Alto Neuroscience, Inc.
ANROUnited States
13 filed reports · 258 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
13 reports · Jan 2024 to Sep 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 41 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 9 | 1,294 | Mar 2024 to Sep 2026 |
| Annual · 10-KSEC EDGAR | 2 | 804 | Dec 2024 to Dec 2025 |
| Registration · 424B4SEC EDGAR | 1 | 67 | Feb 2024 |
| Registration · S-1/ASEC EDGAR | 1 | 4 | Jan 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 10-Q | 2026-09-30 | 2026-11-10 | 281 | Open |
| FY2026 Q2 | 10-Q | 2026-06-30 | 2026-08-12 | 153 | Open |
| FY2026 Q1 | 10-Q | 2026-03-31 | 2026-05-13 | 159 | Open |
| FY2025 | 10-K | 2025-12-31 | 2026-03-16 | 509 | Open |
| FY2025 Q3 | 10-Q | 2025-09-30 | 2025-11-12 | 143 | Open |
| FY2025 Q2 | 10-Q | 2025-06-30 | 2025-08-13 | 103 | Open |
| FY2025 Q1 | 10-Q | 2025-03-31 | 2025-05-14 | 111 | Open |
| FY2024 | 10-K | 2024-12-31 | 2025-03-20 | 295 | Open |
| FY2024 Q3 | 10-Q | 2024-09-30 | 2024-11-12 | 147 | Open |
| FY2024 Q2 | 10-Q | 2024-06-30 | 2024-08-13 | 97 | Open |
| FY2024 Q1 | 10-Q | 2024-03-31 | 2024-05-14 | 100 | Open |
| FY2024 | 424B4 | 2024-02-05 | 2024-02-05 | 67 | Open |
Financial data
258 concepts · 2,169 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial234 concepts · 2,007 facts · Dec 2021 to Sep 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value18 · Mar 2023 to Sep 2026
- Allocated share based compensation expense18 · Mar 2023 to Sep 2026
- Cash cash equivalents restricted cash and restricted cash equivalents18 · Mar 2023 to Sep 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect18 · Mar 2023 to Sep 2026
- Common stock par or stated value per share18 · Mar 2023 to Sep 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents18 · Mar 2023 to Sep 2026
- Fair value adjustment of warrants18 · Mar 2023 to Sep 2026
- General and administrative expense (US GAAP)18 · Mar 2023 to Sep 2026
- Increase decrease in accounts payable18 · Mar 2023 to Sep 2026
- Increase decrease in accrued liabilities and other operating liabilities18 · Mar 2023 to Sep 2026
- Increase decrease in prepaid deferred expense and other assets18 · Mar 2023 to Sep 2026
- Interest expense nonoperating18 · Mar 2023 to Sep 2026
- Interest paid net18 · Mar 2023 to Sep 2026
- Investment income interest18 · Mar 2023 to Sep 2026
- Net cash provided by used in financing activities18 · Mar 2023 to Sep 2026
- Net cash provided by used in investing activities18 · Mar 2023 to Sep 2026
- Net cash provided by used in operating activities18 · Mar 2023 to Sep 2026
- Net income loss18 · Mar 2023 to Sep 2026
- Non-cash interest expense related to term loan18 · Mar 2023 to Sep 2026
- Nonoperating income expense18 · Mar 2023 to Sep 2026
- Operating expenses (US GAAP)18 · Mar 2023 to Sep 2026
- Operating income loss18 · Mar 2023 to Sep 2026
- Operating lease right of use asset amortization expense18 · Mar 2023 to Sep 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent18 · Mar 2023 to Sep 2026
Segment6 concepts · 139 facts · Dec 2023 to Sep 2026
- Research and development expense69 · Dec 2023 to Sep 2026
- Allocated share based compensation expense14 · Dec 2023 to Sep 2026
- Labor and related expense14 · Dec 2023 to Sep 2026
- Net income loss14 · Dec 2023 to Sep 2026
- Other general and administrative expense14 · Dec 2023 to Sep 2026
- Other research and development expense14 · Dec 2023 to Sep 2026
Offering Terms17 concepts · 22 facts · Jan 2024 to Feb 2024
- Planned Use of Offering Proceeds4 · Feb 2024
- Securities Offered by Company2 · Jan 2024 to Feb 2024
- Underwriters Option Securities2 · Jan 2024 to Feb 2024
- Dilution per Security to New Investors1 · Feb 2024
- Lock-Up Period Days1 · Feb 2024
- Net Tangible Book Value per Security After Offering1 · Feb 2024
- Net Tangible Book Value per Security Before Offering1 · Feb 2024
- Offering Gross Proceeds1 · Feb 2024
- Offering Net Proceeds1 · Feb 2024
- Offering Price per Security1 · Feb 2024
- Offering Price Range High1 · Jan 2024
- Offering Price Range Low1 · Jan 2024
- Offering Proceeds Before Expenses per Security1 · Feb 2024
- Offering Proceeds Before Expenses to Company1 · Feb 2024
- Shares Outstanding After Offering1 · Feb 2024
- Underwriting Discount per Security1 · Feb 2024
- Underwriting Discount Total1 · Feb 2024
Geography1 concept · 1 fact · Dec 2024
- Operating lease payments1 · Dec 2024
Segments
140 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 139 facts
- Reportable139 · Dec 2023 to Sep 2026
Statement geographical1 member · 1 fact
- Los Altos California1 · Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary10 claims from 1 report · Sep 2026
- Management discussion (MD&A) commentary41 claims from 2 reports · Feb 2024 to Sep 2026
- Risk-factor changes25 claims from 1 report · Dec 2024
- Risk factors171 risks from 2 annual reports · 2024
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Alto Neuroscience, Inc. (ANRO) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.